Frontage Holdings Corporation (1521.HK)
| Previous close | 1.300 |
| Open | 1.290 |
| Bid | 1.270 x N/A |
| Ask | 1.300 x N/A |
| Day's range | 1.260 - 1.300 |
| 52-week range | 1.210 - 2.580 |
| Volume | |
| Avg. volume | 2,766,832 |
| Market cap | 2.606B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 32.00 |
| EPS (TTM) | 0.040 |
| Earnings date | 28 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.96 |
PR NewswireEPNextS Group and Frontage Laboratories, Inc. Announce Collaboration in Early Phase Clinical Trials in the United States to Improve "Drug Lag" and "Drug Loss" Issues in Japan
EPNextS Group, a Japanese based leading provider of clinical trial solutions, and Frontage Laboratories, Inc., a US based full-service contract research organization (CRO), have announced a collaboration aimed at addressing the challenges of "Drug Lag" and "Drug Loss" in Japan.
PR NewswireFrontage Appoints Mr. Henry Gao as Chief Financial Officer
Frontage Holdings Corporation ("Frontage") is pleased to announce that Mr. Henry Gao has been appointed as its Chief Financial Officer ("CFO"), effective February 1, 2024. As CFO, Mr. Gao will play a key role in planning, implementing, managing and controlling all financial-related activities for Frontage. In parallel to his new role, Mr. Gao will continue to serve his role as President of Asia Pacific and oversee Frontage's operations in the Asia-Pacific region.
- PR Newswire
Frontage Laboratories Acquires Accelera S.r.l.'s Bioanalytical and DMPK Businesses
Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera).
